An official website of the United States government Here's how you know

National Library of Medicine
National Center for Biotechnology Information

Log in

PubMed®

Search

Advanced User Guide

Save Email Send to Display options

Comparative Study > Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1124-30.
doi: 10.1002/pds.2047.

Epidemiologic study of aripiprazole use and the incidence of suicide events

Marianne Ulcickas Yood [1], Gerald Delorenze, Charles P Quesenberry Jr, Ai-Lin Tsai, Syd Phillips, Vincent J Willey, Steve J Niemcryk, Karen Wells, Mary Lou Skovron, Mark J Cziraky, William Carson, Susan A Oliveria

Affiliations + expand

PMID: 20925132 DOI: 10.1002/pds.2047

Abstract

Purpose: Because second generation antipsychotics (SGA) might affect the risk of suicide, systematic assessment of suicide risk associated with SGA in the postmarketing setting is important and of interest to regulatory authorities. To fulfill a postmarketing request, our objective was to determine suicide event (attempted or completed) incidence in patients with schizophrenia or bipolar disorder, prescribed aripiprazole.

Methods: Using administrative data from three US sources, we assessed study endpoints of suicide attempts and death by suicide in patients aged ≥18 enrolled continuously for ≥3 months in their health plans before receiving their first ever antipsychotic (November 2002-December 2005).

Results: Among 20 489 antipsychotic users (8985 patient-years), unadjusted suicide event rates (per 1000 patient-years) were: 20.69 (aripiprazole); 23.99 (olanzapine); 32.33 (quetiapine); 19.69 (risperidone); 48.52 (ziprasidone). Compared with current users of other SGA combined, aripiprazole users did not have an increased risk of suicide events (crude hazard ratio (HR) = 0.79, 95%CI: 0.48-1.30; adjusted HR = 0.69, 95%CI: 0.42-1.14-(controlling for study site, age, sex, index prescription year, antipsychotic use history, other pharmacotherapy exposure, comorbidity presence, schizophrenia/bipolar disorder, suicide attempts, number inpatient/outpatient encounters).

Conclusions: In this large, multi-site study, compared with other SGA combined, aripiprazole is not associated with an increased risk of suicide events in an inception cohort of patients with ICD-9/ICD-10 codes indicative of schizophrenia or bipolar disorder.

Copyright © 2010 John Wiley & Sons, Ltd.

PubMed Disclaimer

FULL TEXT LINKS

WILEY Full Text Article

ACTIONS

Cite

Collections

Permalink

EXPERIMENTAL RESOURCE

Linked Discoveries

PAGE NAVIGATION

Title & authors

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Similar articles

Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.
J Med Econ. 2011;14(6):777-86. doi: 10.3111/13696998.2011.625066. Epub 2011 Sep 29.
PMID: 21954966

Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E, Tourjman V.
Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021.
PMID: 20152550 Review.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.
Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.
PMID: 24119767

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F.
J Med Econ. 2013 Jul;16(7):951-61. doi: 10.3111/13696998.2013.807813. Epub 2013 Jun 7.
PMID: 23701260

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H, Stip E.
Expert Opin Drug Saf. 2012 Sep;11(5):713-32. doi: 10.1517/14740338.2012.712682.
PMID: 22913713

See all similar articles

Cited by

Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.
Tondo L, Baldessarini RJ.
Curr Psychiatry Rep. 2016 Sep;18(9):88. doi: 10.1007/s11920-016-0715-0.
PMID: 27542851 Review.

Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia.
Taipale H, Lähteenvuo M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J.
Schizophr Bull. 2021 Jan 23;47(1):23-30. doi: 10.1093/schbul/sbaa111.
PMID: 33428766 Free PMC article.

Aripiprazole: a review of its use in the management of schizophrenia in adults.
Croxtall JD.
CNS Drugs. 2012 Feb 1;26(2):155-83. doi: 10.2165/11208400-000000000-00000.
PMID: 22296317 Review.

Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.
Dhillon S.
Drugs. 2012 Jan 1;72(1):133-62. doi: 10.2165/11208320-000000000-00000.
PMID: 22191800 Review.

Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and without diabetes in the U.S.
Suaya JA, Eisenberg DF, Fang C, Miller LG.
PLoS One. 2013 Apr 10;8(4):e60057. doi: 10.1371/journal.pone.0060057. Print 2013.
PMID: 23593162 Free PMC article.

See all "Cited by" articles

Publication types

> Comparative Study
> Multicenter Study

MeSH terms

> Adult
> Antipsychotic Agents / adverse effects*
> Antipsychotic Agents / therapeutic use
> Aripiprazole
> Bipolar Disorder / drug therapy
> Databases, Factual
> Female
> Humans
> Incidence
> Male
> Middle Aged
> Piperazines / adverse effects*
> Piperazines / therapeutic use
> Quinolones / adverse effects*
> Quinolones / therapeutic use
> Risk
> Schizophrenia / drug therapy
> Suicide / statistics & numerical data*
> Suicide, Attempted / statistics & numerical data*
> Young Adult

Substances

> Antipsychotic Agents
> Piperazines
> Quinolones
> Aripiprazole

Related information

Cited in Books
PubChem Compound
PubChem Compound (MeSH Keyword)
PubChem Substance

LinkOut - more resources

Full Text Sources
Ovid Technologies, Inc.
Wiley

Medical
MedlinePlus Health Information

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

FOLLOW NCBI

Connect with NLM

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

Web Policies
FOIA
HHS Vulnerability Disclosure

Help
Accessibility
Careers

NLM | NIH | HHS | USA.gov